Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas-Reference-Cited by-同舟云学术

Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas

Published:2023-11 Issue:11 Volume:34 Page:1055-1063
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Song Y.,Yoon D.H.,Yang H.,Cao J.,Ji D.,Koh Y.,Jing H.,Eom H.,Kwak J.,Lee W.,Lee J.,Shin H.,Jin J.,Wang M.,Yang Z.,Kim W.S.,Zhu J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference30 articles.

1. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes;Vose;J Clin Oncol,2008

2. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project;Bellei;Haematologica,2018

3. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study;O'Connor;J Clin Oncol,2011

4. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy;Coiffier;J Clin Oncol,2012

5. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study;O'Connor;J Clin Oncol,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Golidocitinib favorable for relapsed/refractory T‐cell lymphoma;Cancer;2024-03-18

2. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study;The Lancet Oncology;2024-01